Amarantus to Present at the 2015 Aegis Growth Conference
October 05 2015 - 10:48AM
Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology
company developing therapeutic and diagnostic product candidates in
orphan indications and neurology, today announced that it will be
presenting at the 2015 Aegis Growth Conference being held October
7-9, 2015 in Las Vegas, Nevada.
Gerald E. Commissiong, President & CEO of
Amarantus, will present a corporate update on Friday, October 9,
2015 at 11:25 a.m. PDT.
As part of his presentation, Mr. Commissiong
will discuss the Company’s recently announced strategic focus on
the near-term development efforts for its Engineered Skin
Substitute (ESS) program as a treatment for rare pediatric
diseases, including pediatric severe burns and Congenital Giant
Hairy Nevus.
A live webcast of the presentation may be
accessed via the Amarantus IR Calendar located on the News and
Events page of the Investor Relations section of the Company’s
website (www.amarantus.com). The webcast replay will be available
approximately two hours after the presentation ends and will be
archived for 30 days.
About Engineered Skin Substitute
(ESS)
Engineered Skin Substitute (ESS) is a
tissue-engineered skin prepared from autologous (patient's own)
skin cells. It is a combination of cultured epithelium with a
collagen-fibroblast implant that produces a skin substitute that
contains both epidermal and dermal components. This model has been
shown in preclinical studies to generate a functional skin barrier.
Most importantly, self-to-self skin grafts for autologous skin
tissue are less likely to be rejected by the immune system of the
patient, unlike with porcine or cadaver grafts in which immune
system rejection is a possibility. ESS has been used in an
investigator initiated clinical setting in over 130 human subjects,
primarily pediatric patients, for the treatment of severe burns up
to 95% total body surface area.
About Amarantus BioScience Holdings,
Inc.
Amarantus BioScience Holdings (OTCQX:AMBS) is a
biotechnology company developing treatments and diagnostics for
diseases in the areas of neurology and orphan diseases. The Company
has an exclusive worldwide license to intellectual property rights
associated to Engineered Skin Substitute (ESS), an orphan drug
designated autologous full thickness skin replacement product in
development for the treatment of adult severe burns currently
preparing to enter Phase 2 clinical studies. The Company is
currently evaluating human clinical data from previously conducted
studies in pediatric severe burns and Congenital Giant Hairy Nevus
to support clinical development expansion into those areas.
AMBS also has development rights to eltoprazine, a small molecule
currently in a Phase 2b clinical program for Parkinson's disease
levodopa-induced dyskinesia with the potential to expand into adult
ADHD and Alzheimer's aggression. AMBS owns the intellectual
property rights to a therapeutic protein known as
mesencephalic-astrocyte-derived neurotrophic factor (MANF) and is
developing MANF as a treatment for orphan ophthalmic disorders,
initially in retinitis pigmentosa (RP) and retinal artery occlusion
(RAO). AMBS also owns the discovery of neurotrophic factors
(PhenoGuard™) that led to MANF's discovery.
AMBS' Diagnostics division owns the rights to
MSPrecise®, a proprietary next-generation DNA sequencing (NGS)
assay for the identification of patients with relapsing-remitting
multiple sclerosis (RRMS) at first clinical presentation, has an
exclusive worldwide license to the Lymphocyte Proliferation test
(LymPro Test®) for Alzheimer's disease, which was developed by
Prof. Thomas Arendt, Ph.D., from the University of Leipzig, and
owns intellectual property for the diagnosis of Parkinson's disease
(NuroPro).
For further information please visit
www.Amarantus.com, or connect with the Company on Facebook,
LinkedIn, Twitter and Google+.
Forward-Looking
StatementsCertain statements, other than purely historical
information, including estimates, projections, statements relating
to our business plans, objectives, and expected operating results,
and the assumptions upon which those statements are based, are
forward-looking statements. These forward-looking statements
generally are identified by the words "believes," "project,"
"expects," "anticipates," "estimates," "intends," "strategy,"
"plan," "may," "will," "would," "will be," "will continue," "will
likely result," and similar expressions. Forward-looking statements
are based on current expectations and assumptions that are subject
to risks and uncertainties which may cause actual results to differ
materially from the forward-looking statements. Our ability to
predict results or the actual effect of future plans or strategies
is inherently uncertain. Factors which could have a material
adverse effect on our operations and future prospects on a
consolidated basis include, but are not limited to: changes in
economic conditions, legislative/regulatory changes, availability
of capital, interest rates, competition, and generally accepted
accounting principles. These risks and uncertainties should also be
considered in evaluating forward-looking statements and undue
reliance should not be placed on such statements.
Investor and Media Contact:
Jenene Thomas
Jenene Thomas Communications, LLC
Investor Relations and Corporate Communications Advisor
T: (US) 908.938.1475
E: jenene@jenenethomascommunications.com
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Sep 2023 to Sep 2024